==Amicus Therapeutics (FOLD) has entered into a License Agreement with Teva Pharmaceuticals (TEVA)

 

Amicus Therapeutics has entered into a License Agreement with Teva Pharmaceuticals USA, Inc. and Teva Pharmaceuticals, Inc.

• This Agreement resolves the patent litigation brought by Amicus in response to Teva's Abbreviated New Drug Application seeking approval to market a generic version of GALAFOLD 123mg capsules prior to expiration of the applicable patents.
• Pursuant to the terms of the Agreement, Amicus will grant Teva a license to market its generic version of GALAFOLD in the United States beginning on January 30, 2037, if approved by the U.S. Food and Drug Administration and unless certain limited circumstances customarily included in these types of agreements occur. In accordance with the Agreement, the parties will terminate all ongoing Hatch-Waxman litigation between Amicus and Teva regarding GALAFOLD patents pending in the U.S. District Court for the District of Delaware. The litigation will continue against Aurobindo1 as the remaining active party and the litigation stay remains in place for Lupin.
  
• As required by law, the companies will submit the confidential license agreement to the U.S. Federal Trade Commission and the U.S. Department of Justice for review.

Unusual Options Activity Fri 4/12/24

The following options are exhibiting notable trading, potentially indicating changing sentiment toward the underlying stocks, and/or potentially representing positioning for increased volatility.

Bullish Call Activity:

• MRSN Aug 5 calls (volume: 3550, open int: 0, implied vol: ~180%, prev day implied vol: 138%). Co is expected to report earnings early May.
• CDE Apr 5.5 calls (volume: 9130, open int: 160, implied vol: ~109%, prev day implied vol: 81%). 7250 contracts traded in a single transaction. Co is confirmed to report earnings May 1 before the open.
• RIG Jun 5 calls (volume: 6020, open int: 10, implied vol: ~71%, prev day implied vol: 64%). 1950 contracts traded in a single transaction. Co is confirmed to report earnings April 29 before the open.

Bearish Put Activity:

• APLD Apr 4 puts are seeing interest with the underlying stock down 7% (volume: 7000, open int: 700, implied vol: ~250%, prev day implied vol: 177%). Co reported earnings last night.
• TEVA Apr 12.5 puts are seeing interest with the underlying stock down 5% (volume: 7020, open int: 0, implied vol: ~44%, prev day implied vol: 34%). 1350 contracts traded in a single transaction. Co is confirmed to report earnings May 8 before the open.

Sentiment: The CBOE Put/Call ratio is currently: 0.98, VIX: (18.62, +3.71, +24.8%).
April 19 is options expiration -- the last day to trade April equity options.

===Teva Pharma (TEVA) : therapy for Atopic Dermatitis and Asthma

 

Teva Pharma and Biolojic Design announces an exclusive license agreement to develop a potential novel antibody-based therapy for the treatment of Atopic Dermatitis and Asthma

• Biolojic's BD9 is a multibody that was computationally designed as a multi specific antibody targeting IL-13 / TSLP to treat inflammatory diseases.
• Agreement builds on Teva's Pivot to Growth strategy to step up innovation on Teva's innovative pipeline.
  
• Teva to obtain exclusive worldwide rights to develop and commercialize BD9 multibody for potential treatment for Atopic Dermatitis and Asthma

Unusual Options Activity Wed 9/13/23

Stocks seeing volatility buying (bullish call buying/bearish put buying):

Calls:

• TEVA Sept 8 calls are seeing interest with 105 contracts trading vs. open int of 10760, pushing implied vol up around 93 points to ~260.72%. The Co is expected to report its next earnings in late October/ early November
  
• FSLY Sept 12.50 calls are seeing interest with 120 contracts trading vs. open int of 630, pushing implied vol up around 206 points to ~325.6%. The Co is expected to report its next earnings in late October/early November

Puts:

• VFS Sept 70 puts are active with 60 contracts trading vs. open int of 1240, pushing implied vol down around 368 points to ~968.24%. There was a Barrons report that half of its 2023 EV sales were to a taxi company, controlled by itself
  
• SMTC Sept 21 puts are active with 110 contracts trading vs. open int of 2570, pushing implied vol down around 86 points to ~259.77%. The Co will report this afternoon

Sentiment: The CBOE Put/Call ratio is currently: 1.03, VIX: (13.44, -0.79, -5.55%).
September 15 is options expiration -- the last day to trade September equity options.

-=Teva Pharma (TEVA) reported earnings on Wed 9 Feb 22 (b/o)

 

Teva Pharma beats by $0.04, misses on revs; guides FY22 EPS below consensus, revs below consensus 

• Reports Q4 (Dec) earnings of $0.77 per share, excluding non-recurring items, $0.04 better than the S&P Capital IQ Consensus of $0.73; revenues fell 7.9% year/year to $4.1 bln vs the $4.28 bln S&P Capital IQ Consensus.
• Co issues downside guidance for FY22, sees EPS of $2.40-$2.60, excluding non-recurring items, vs. $2.67 S&P Capital IQ Consensus; sees FY22 revs of $15.6-$16.2 bln vs. $16.29 bln S&P Capital IQ Consensus.
  • "In 2021 Teva delivered solid results, generating strong cash flow and improving our profitability. While COVID-19 continued to impact patient behavior and global prescribing patterns, we continued to optimize our supply chain and manufacturing capabilities to provide essential medicines to the millions of patients who rely on us throughout the world. We improved our gross and operating margin and reduced our net debt, keeping us on our path to achieve our 2023 long-term goals", said Mr. Kre Schultz, Teva's President and CEO. Mr. Schultz continued: "Looking forward to 2022, we expect to see continued growth of our key products AUSTEDO and AJOVY, as well as to continue to advance our core business through the launch of high quality generic medicines around the world. We are also excited about the expected FDA approval and launch of Risperidone LAI, an important treatment for patients suffering from schizophrenia."

Earnings this week : Feb 7 - 11, 2022 (wk 6)

Monday (Feb 7)

• Morning:  AMG CRNC CNA ENR GTES HAS ON TSN ZBH
• Afternoon: ACM AOSL AMGN ACLS BRX CHGG DHT KMT KFRC LEG NUAN PDM PFG RMBS SLQT SPG SSD SNCY TTWO THC TDC VRNS

Tuesday (Feb 8)

• Morning: AGCO ARMK AVNT BP CARR CVE CNC CNHI COTY CTS DD EPC FISV IT HAE HOG INCY KKR LEA MBUU MAS NRZ NVT PFE POLY SPGI SYY TMHC TRI TDG VIRT VSH WMG
• Afternoon:  ATGE AIZ ATO AZTA CMG CNO CMP CRSR CCK DCPH APPS DEI DOCS EGP ENPH ESE FLT FMC GFS PEAK HIW HUBG ICHR INSP JKHY LBRT LYFT MNDT MODN NCR NEWR OMC ONTO PAYC PTON QGEN QNST SCSC SAVE STEP STE TRMB TSE UDR VVV VREX VOYA XPO YUMC

Wednesday (Feb 9)

• Morning:  ARCC AVYA BDC BXMT BG CCJ CGC CDW CHEF CME CRTO CVS FOXA HMC IIVI LAD MSGE NNN PAG PFGC RDWR REYN SITC TEVA TGI YUM
• Afternoon:  TWOU AEIS AFG NLY ACGL ASGN BKH CDAY CHX CPA CXW DCP DIOD ENS NVST EQT EFX EQC EEFT RE FR FLNC FWRD ULCC GFL PI IFF IRBT ITT KN RAMP LUMN MFC MAT MDU MESA MGM MC MOH MSI ORLY PEP PPC PAA RPD REXR SGEN SONO SPSC SLF TTMI TWLO TWO UBER UDMY VMEO DIS WTS ZNGA

Thursday (Feb 10)

• Morning: ALNY MT AZN CAMT GOOS ECOM KO CIGI CYBR DDOG DBD DTE DUK FAF GPN GPI HRI HII INMD NSIT IPG K KIM LH LCII LECO LIN MAC MLM MCO PATK PTEN PBF BTU PCG PM PIPR PDS ROLL SSTK SON TPR TTGT TU TUFN TWTR WSO WEX ZBRA
• Afternoon:  ME AFRM AVLR BIO BL BE BHF ELY CSL CC NET COHU CFLT OFC COUR DVA DXCM EQH EXPE FRT FE FLO FRSH GDDY HUBS ILMN NSP FROG MTD MHK MNTV MPWR NWE PRO QLYS REG RSG SSNC TEX RARE UPWK VRSN VCRA WU YELP ZEN ZG

Friday (Feb 11)  

• Morning:  AB AXL APO ARES BRKR CAE CLF D ENB ESNT FTS G GT GPRE IAA MGA COOP NBIX NWL NMRK PRLB SXT UAA WPC

-=Teva Pharma (TEVA) reported earnings on Wed 27 Oct 21 (b/o)

 

Teva Pharma misses by $0.06, misses on revs; reaffirms FY21 EPS guidance, revs guidance

• Reports Q3 (Sep) earnings of $0.59 per share, $0.06 worse than the S&P Capital IQ Consensus of $0.65; revenues fell 2.8% year/year to $3.89 bln vs the $4.05 bln S&P Capital IQ Consensus.
• Co reaffirms guidance for FY21, sees EPS of $2.50-2.70 vs. $2.60 S&P Capital IQ Consensus; sees FY21 revs of $16.0-16.4 bln vs. $16.35 bln S&P Capital IQ Consensus.

=Teva Pharma (TEVA) reported earnings on Thur 7 May 20 (b/o)

Teva Pharma beats by $0.17, beats on revs; reaffirms FY20 EPS in-line, revs in-line

Reports Q1 (Mar) earnings of $0.76 per share, excluding non-recurring items, $0.17 better than the S&P Capital IQ Consensus of $0.59; revenues rose 5.0% year/year to $4.36 bln vs the $4.15 bln S&P Capital IQ Consensus.

Co issues in-line guidance for FY20, sees EPS of $2.30-2.55 vs. $2.44 S&P Capital IQ Consensus; sees FY20 revs of $16.6-17.0 bln vs. $16.74 bln S&P Capital IQ Consensus.

Earnings this week : May 4 - 8, 20 (wk 19)

Monday (May 4)

• Morning: PETS GATX KELYA PFGC NNN PETS PBI TSN WAB WEC WLK 
• Afternoon:  ACHC ALSN AIG AWR CAR CHGG DLB FN FIVN FRPT ITRI JKHY KMT KN LEG LMNX MHK MOS RMBS O RBC REXR SHAK SWKS SYKE THC TXRH TREX VNOM VNO WWD XPO

Tuesday (May 5)

• Morning: ACM AER AMCX APTV ARMK ARCC DBD D DD DEA FCAU GPI HSIC ITW INCY INGR IPGP JELD JLL TREE LGIH LPX LITE MNK MPC SBSI SYY TRI BLD TDG USCR USFD W WBT WRK
• Afternoon: ATVI ANET BYND BLKB CAMP CAKE COHU CMP DVA DK DVN EA ICFI IOSP INGN INSP NVTA JAZZ KGC KLAC LC LPSN DOOR MTCH MATX MAT MELI MEOH MGNX MODN MYGN NVRO ONTO PINS PAA PLNT PRO PRU SFM STOR VRSK VOYA DIS WU

Wednesday (May 6)

• Morning: AEIS ALXN ARES ASTE BWA BG CARS CBZ CDW FUN IMOS CNHI CGEN CVS DISCA GCP GM GEL GPC ROCK GPN KL KKR MYE NYT DNOW NS ODP OMI PZZA PSN PAG SBH STNG SMG SHOP TMHC TNC MEET VMC WD WM WEN WING WYND ZTS
• Afternoon: DDD ADTN ALB AYX AMED AEL AWK AMP ANGI ANSS APA AZPN ATO AVB BNFT BIO BEAT EPAY BFAM BRKR CCMP CVNA CTL CDAY CF CHEF XEC CPA CXW CSGS CUB CW DAR DCP DRQ ENTA EPR EQIX ESE ESPR WTRG ESS ETSY RE EVRG ES EXAS STAY EXR FSLY FRT FG FORM FTNT FCPT FOXA FOXF FNV GBT GDDY GRUB HR HI HUBS H IMMU INSG IAC INVH IRWD KRO LCI LGND LNC LVGO LYFT CLI MX MFC MRO MET MAA NTRA NBIX LASR NMIH NDLS NUS NTR NUVA OSUR PAAS PYPL PTON PING PXD PPD QTWO QGEN QDEL RDN RMAX RP RNR RCII REZI RNG RGLD SRPT SEDG SONO SJI SAVE SQ STAA SRI RUN TMUS TLND TTGT REAL TIVO TRMB TSE TROX TWLO TWO UDR UGI RARE UPWK VVV VIAV WCN WTS WELL WPM WPX WYNN ZIXI ZNGA 

Thursday (May 7)

• Morning: AAON AAN ACIW GOLF AES ABC BUD MT AAWW BLL BHC BCE BDX BV BMY CNQ CNNE CBRE CNP ECOM CRL CWEN CCOI CFX COMM CTB CORE CTVA DHR DISH SATS EPC EDIT ELAN ENB ENDP ENR EPAM EQT EXLS FIS FVRR FOCS IT THRM GTN HAIN HL HES HLT HIMX HFC HII NSIT IART NTLA IDCC IRM JBLU KAR KTB LAMR LAUR LXP MGA MBUU MMS MD MIDD MRNA MUR EYE NTCT NOMD OGE PCRX PEGI PENN PRFT DOC PBH PWR RTX RHP SERV SHLX SPAR SRCL TGNA TU TEVA TW THS VIAC VIRT VSTO VG WEX XEL YETI 
• Afternoon: ADT AL ALRM APPN AAXN BECN BILL BJRI BKNG CTSH SCOR ED CCRN DBX ENV EOG FSLR FISV GLUU GPRO LOPE GH HLF ICUI IPHI PODD ITGR LHCG LSI LYV MTW VAC MCHP MNST NWSA NUAN OMCL PDCE PEB PBA PRAA PFPT PBYI QRVO QLYS RPD RDFN RBA ROKU SKYW STMP SPWR SVMK SYNA TDC TTD TRUE TCX UBER OLED UPLD ECOL YELP ZG 

Friday (May 8) 

• Morning: AXL ATH AVA BLMN BPMP BR BIP CATM REOAD CRON UFS ESNT EVTC EVOP EXC GTT HEES HSC HMSY TWNK TILE KIM LEA NJR NBL OUT PBF PNW PPL SABR SSP SEAS SR SHO SWCH TEN VTR

*******

Earnings spotlight: Tyson Foods (NYSE:TSN), Shake Shack (NYSE:SHAK), Skyworks Solutions (NASDAQ:SWKS), Freshpet (NASDAQ:FRPT) and Chegg (NYSE:CHGG) on May 4; Marathon Petroleum (NYSE:MPC), Fiat Chrysler Automobiles (NYSE:FCAU), Sysco (NYSE:SYY), Beyond Meat (NASDAQ:BYND), US Foods (NYSE:USFD), DuPont (NYSE:DD), Activision Blizzard (NASDAQ:ATVI), Disney (NYSE:DIS), Prudential (NYSE:PRU), Allstate (NYSE:ALL) and Dominion Energy (NYSE:D) on May 5; CVS Health (NYSE:CVS), General Motors (NYSE:GM), Bunge (NYSE:BG), Barrick (NYSE:GOLD), MetLife (NYSE:MET), T-Mobile US (NASDAQ:TMUS), Etsy (NASDAQ:ETSY), Shopify (NYSE:SHOP), Peloton Interactive (NASDAQ:PTON) and PayPal (NASDAQ:PYPL) on May 6; AmerisourceBergen (NYSE:ABC), JetBlue (NASDAQ:JBLU), Booking Holdings (NASDAQ:BKNG), Raytheon Technologies (NYSE:RTX), Anheuser-Busch InBev (NYSE:BUD), Bristol-Myers Squibb (NYSE:BMY), ViacomCBS (NASDAQ:VIAC), Baidu (NASDAQ:BIDU), Uber (NYSE:UBER), News Corp (NASDAQ:NWSA) and Post Holdings (NYSE:POST) on May 7; and SeaWorld Entertainment (NYSE:SEAS), Cronos (NASDAQ:CRON) and PBF Energy (NYSE:PBF) on May 8.

-=Teva Pharma (TEVA) could face billions in damages from opioid lawsuits, analyst says

One analyst is getting shaky on Teva Pharmaceuticals stock (ticker: TEVA) after two weeks of iffy legal news for the Israeli drugmaker.

UBS’s Navin Jacob downgraded Teva to Neutral from Buy, and cut his target share price to $12 from $22, in a note out Monday morning. The note comes days after Teva said it would pay $85 million to the state of Oklahoma to settle a lawsuit over its role in the production and marketing of opioids.

----

Teva settles with Oklahoma for $85 million in opioid case
Associated Press Associated PressMay 26, 2019
NORMAN, Okla. (AP) — One of the drugmakers named in Oklahoma's lawsuit over the opioid crisis has agreed to a settlement in which it will pay the state $85 million.

Israeli-owned Teva Pharmaceuticals and Oklahoma Attorney General Mike Hunter both announced the settlement Sunday in separate statements. Teva, its related affiliates and Johnson & Johnson and several of its subsidiaries were set to go to trial Tuesday in Norman.

Hunter said the case against Johnson & Johnson will proceed on schedule.

He also said the funds from the settlement with Teva will be used to fight the opioid crisis in Oklahoma.

Teva did not admit any wrongdoing under the settlement.

Earlier this year, Oklahoma settled with OxyContin-maker Purdue Pharma for $270 million.

=Teva Pharma (TEVA) reported earnings on Thur 2 May 2019 (b/o)

Teva Pharma beats by $0.02, misses on revs; reaffirms FY19 EPS, revs guidance

• Reports Q1 (Mar) earnings of $0.60 per share, excluding non-recurring items, $0.02 better than the S&P Capital IQ Consensus of $0.58; revenues fell 15.2% year/year to $4.29 bln vs the $4.38 bln S&P Capital IQ Consensus.
  • Revenues decreased 15%, or 12% in local currency terms, compared to the first quarter of 2018, mainly due to generic competition to COPAXONE and a decline in revenues from the co's respiratory products and U.S. generics business.
• "We faced the expected loss of exclusivities of key products COPAXONE and ProAir to generic competition. Our focus is on stabilizing our global generics business and ensuring the success of our long-term organic growth drivers, especially AJOVY and AUSTEDO. Both products continue to gain momentum since their initial launches and we are making the necessary investments to be able to bring them to markets outside of the U.S. as well as explore additional indications."
• EBITDA (non-GAAP operating income, which excludes amortization and certain other items, as well as depreciation expenses) was $1,154 million in the first quarter of 2019, a decrease of 27% compared to $1,587 million in the first quarter of 2018.
• Co reaffirms guidance for FY19, sees EPS of $2.20-2.50, excluding non-recurring items, vs. $2.40 S&P Capital IQ Consensus; sees FY19 revs of $17-17.4 bln vs. $17.31 bln S&P Capital IQ Consensus.

=Teva Pharma (TEVA) reported earnings on Wed 13 Feb 2019 (b/o)

Teva Pharma misses by $0.02, reports revs in-line; guides FY19 EPS below consensus, revs below consensus

• Reports Q4 (Dec) earnings of $0.53 per share, excluding non-recurring items, $0.02 worse than the S&P Capital IQ Consensus of $0.55; revenues fell 15.5% year/year to $4.56 bln vs the $4.52 bln S&P Capital IQ Consensus.
• GAAP gross profit margin was 43.2% in the fourth quarter of 2018, compared to 45.3% in the fourth quarter of 2017. Non-GAAP gross profit was $2,328 million in the fourth quarter of 2018, a decline of 15% from the fourth quarter of 2017.
• Co issues downside guidance for FY19, sees EPS of $2.20-2.50, excluding non-recurring items, vs. $2.82 S&P Capital IQ Consensus; sees FY19 revs of $17.0-17.4 bln vs. $17.99 bln S&P Capital IQ Consensus.

Earnings this week : Feb. 11 - 15, 2019 (wk 7)

Earnings confirmed to report this week:

Monday (Feb 11)

• Morning: CNA DO GPRE KMPR L MCY MDP MPAA NSP QSR
• Afternoon: AMBR, AMKR ACB BHF BRS BRX BRKR CHGG CMP ROAD DCP ELVT RE FARM FMC RAMP MIME MOH MGI LABL NWE OHI OMF PYX RNG VRNS VECO VNO 

Mon pm/Tue am (vol): https://finviz.com/screener.ashx?v=211&t=AMBR,AMKR,ACB,BHF,BRS,BRX,BRKR,CHGG,CMP,ROAD,DCP,ELVT,RE,FARM,FMC,RAMP,MIME,MOH,MGI,LABL,NWE,OHI,OMF,PYX,RNG,VRNS,VECO,VNO,AYR,ARCC,FIS,HUN,IPGP,JLL,MLM,MDSO,TAP,NNN,NP,NRZ,OMC,ONDK,SABR,SHOP,STE,TOWR,UAA,USFD,WEC,WELL&ta=0&o=-volume

Tuesday (Feb 12)

• Morning: AYR ARCC FIS HUN IPGP JLL MLM MDSO TAP NNN NP NRZ OMC ONDK SABR SHOP STE TOWR UAA USFD WEC WELL 
• Afternoon: ACGL AIZ AKAM AQ ATVI AVLR BFAM BXMT CNO CRAY CSOD DEI DENN EXEL GRPN HUBS IRTC JCOM KRNT LSCC MPWR OXY QLYS QUOT REXR RPAI RRR SHO SPSC TRIP TWLO UDR UIS

Tue pm/Wed am (vol):  https://finviz.com/screener.ashx?v=211&ta=0&o=-volume&t=ACGL,AIZ,AKAM,AQ,ATVI,AVLR,BFAM,BXMT,CNO,CRAY,CSOD,DEI,DENN,EXEL,GRPN,HUBS,IRTC,JCOM,KRNT,LSCC,MPWR,OXY,QLYS,QUOT,REXR,RPAI,RRR,SHO,SPSC,TRIP,TWLO,UDR,UIS,AB,ACCO,BABY,BKI,CAMT,CBM,CBRE,CBZ,CEVA,CFX,CIGI,CIM,CRL,CRTO,CVE,DBD,DISH,ECOM,FLIR,FUN,GLPI,GOLD,GPN,HLT,IPG,IRWD,KELY-A,LAD,LPX,LXFT,NVMI,TECK,TEVA,TMHC,WH

Wednesday (Feb 13)

• Morning: AB ACCO BABY BKI CAMT CBM CBRE CBZ CEVA CFX CIGI CIM CRL CRTO CVE DBD DISH ECOM FLIR FUN GLPI GOLD GPN HLT IPG IRWD KELY.A LAD LPX LXFT NVMI TECK TEVA TMHC WH 
• Afternoon: AIG AKR AMGP ANDE AR ARES ARI ASGN BAND BCOV BKD CF CHEF CPA CRY CSCO CTL CTRE CXP DIOD DVA EQC EQIX FCPT FNF FOSL FR FRT H HCP HR IFF IVC KAI KGC LPI MFC MGM MRO NGVT NLY NPO NTAP NUS OII OIS PGRE PPC PRSP PS PXD QDEL QTWO REG RYAM SKT SLF SNBR SPWR STAG SVMK SWIR TCO TCX TRUP TSE VNDA WCN WMB YELP

Thursday (Feb 14)

• Morning: AAN AEE AER AGIO ALE ALKS ARCH AVP AZN BAM BCOR BGCP BLMN BWA CBB CCEP CME COWN CYBR DGX DNOW DUK EEX EPAM EQM EQT FAF GEO GLOG GNRC GOOS GTLS HII HPP INCY IQV IRM KO LECO MANU MGP MTRN NICE NSIT PATK PBF PBFX PDS POOL PPL R SIX SMI SMP SON STFC STNG THS TPX TRP TRTN TRU TU VMC WLH WM WSO WST YETI ZBRA ZTS
• Afternoon: AEM AIRG AMAT AMN ANET AUY BL CBS CC CGC CGNX CPS CVA ELLI GLOB HTA INVH  LOGM  MERC MRC MX NVDA PDFS RDFN RWT SPXC SSNC TLND TNET TREX TRUE VICI WES WGP WRE XPO 

Friday (Feb 15)

• Morning: ABR AXL CHH CPSI DAN DE TSX:ENB FTS MCO NWL PEP POR SXT TYPE WBC YNDX ZEUS

-=Teva Pharma (TEVA) reported earnings on Thur 1 Nov 2018 (b/o)

• Topped Q3 earnings expectations by $0.14 on revs that fell 19.4% year/year to fall in-line with consensus; raised FY18 EPS guidance above consensus while raising the low end of its FY18 revs target; co indicated that revenue decline was connected largely to loss of revenues following certain divestitures as well as price erosion and competition to COPAXONE arising from shifts in the U.S. generics business, though co management notes that COPAXONE "continues to maintain its market share" despite revenue decrease; AUSTEDO saw "strong growth."

Teva Pharma beats by $0.14, reports revs in-line; raises FY18 EPS above consensus, tweaks rev, in-line

Reports Q3 (Sep) earnings of $0.68 per share, $0.14 better thanthe S&P Capital IQ Consensus of $0.54; revenues fell 19.4% year/year to $4.53 bln vs the $4.54 bln S&P Capital IQ Consensus, or 18% in local currency terms, compared to the third quarter of 2017, mainly due to generic competition to COPAXONE, price erosion in our U.S. generics business and loss of revenues following the divestment of certain products and discontinuation of certain activities.

Co issues guidancefor FY18, raises EPS to $2.80-2.95 from $2.55-2.80, excluding non-recurring items, vs. $2.78 S&P Capital IQ Consensus; sees FY18 revs of $18.6-19.0 bln from $18.5-19.0 bln vs. $18.85 bln S&P Capital IQ Consensus.

=Teva Pharma (TEVA) reported earnings on Thur 3 May 2018 (b/o)

Teva Pharma beats by $0.27, beats on revs; raises FY18 guidance 

• Reports Q1 (Mar) earnings of $0.94 per share, excluding non-recurring items, $0.27 better than the Capital IQ Consensus of $0.67; revenues fell 10.0% year/year to $5.07 bln vs the $4.8 bln Capital IQ Consensus.
• Co issues raised guidancefor FY18, sees EPS of $2.40-2.65 from $2.25-2.50 vs. $2.42 Capital IQ Consensus Estimate; sees FY18 revs of $18.5-19.0 bln from $18.3-18.8 bln vs. $18.62 bln Capital IQ Consensus Estimate.

-=Teva Pharma (TEVA) unveils restructuring plan

Teva Pharma unveils restructuring plan and additional measures to improve business and financial performance, workforce to be reduced by over 25%, dividend suspended on ordinary shares and ADSs  

The two year restructuring plan announced today is intended to reduce Teva's total cost base by $3 billion by the end of 2019, out of an estimated cost base for 2017 of $16.1 billion. More than half of the reduction is expected to be achieved by the end of 2018. The company expects to record a restructuring charge as a result of the implementation of the plan in 2018 of at least $700 million, mainly related to severance costs, with additional charges possible following decisions on closures or divestments of manufacturing plants, R&D facilities, headquarters and other office locations.

• These steps are expected to result in the reduction of 14,000 positions globally -- excluding the impact of any future divestments -- over 25% of Teva's total workforce -- over the next two years.
• The majority of the reductions are expected to occur in 2018, with most of the affected employees being notified within the next 90 days. Restructuring efforts will be done in accordance with applicable local requirements. Consultations with the relevant employee representatives will begin in the near term.
• In addition to the restructuring plan, Teva is announcing the following measures to address the company's financial situation:
  • The company will immediately suspend dividends on ordinary shares and ADSs, while dividends on mandatory convertible preferred shares will be evaluated on a quarterly basis per current practice
  • Teva's annual bonus for 2017 will not be paid due to the fact that the company's financial results are significantly below our original guidance for the year.
  • The company will continue to review the potential for additional divestment of non-core assets

Teva will provide full guidance for 2018 in February with the annual results and will share a longer-term strategic direction for the company later in 2018.

=Teva Pharma (TEVA) reported earnings on Thur 2 Nov 2017 (b/o)

Teva Pharma misses by $0.03, reports revs in-line; guides Q4 EPS below consensus, revs below consensus

• Reports Q3 (Sep) earnings of $1.00 per share, excluding non-recurring items, $0.03 worse than the Capital IQ Consensus of $1.03; revenues rose 0.8% year/year to $5.61 bln vs the $5.61 bln Capital IQ Consensus. 
  • Generic medicines revenues in the third quarter of 2017 were $3.0 billion, a decrease of 8% compared to the third quarter of 2016. Generic revenues consisted of: U.S. revenues of $1.2 billion, down 9% compared to the third quarter of 2016, mainly due to challenging market dynamics including pricing declines resulting from customer consolidation into larger buying groups and accelerated FDA approvals for additional generic versions of competing off-patent medicines, partially offset by the inclusion of three months of Actavis Generics revenues in this quarter, compared to two months in the third quarter of 2016.
  • Specialty medicines revenues in the third quarter of 2017 were $2.0 billion, down 1% compared to the third quarter of 2016. U.S. specialty medicines revenues were $1.5 billion, down 4% compared to the third quarter of 2016.
  • Global revenues of Copaxone (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, were $1.0 billion, a decrease of 7% compared to the third quarter of 2016. In October 2017, the FDA approved a generic version of Copaxone 40 mg /mL and an additional generic version of Copaxone 20 mg/mL. A generic version of Copaxone 40 mg /mL was launched in the U.S. market. In the EU, a hybrid version of Copaxone 40 mg/mL was approved. Copaxone revenues in the United States, were $802 million, a decrease of 8% compared to the third quarter of 2016, due to lower volumes of Copaxone 20 mg/mL, negative net pricing effects, mainly as a result of an increase in managed care rebate accruals for inventory in the channel following the FDA approvals for additional generic competition, partially offset by a price increase of 7.9% in January 2017 for both the 20 mg/mL and 40 mg/mL versions.
• Co issues downside guidance for Q4, sees EPS of $0.70-0.80, excluding non-recurring items, vs. $1.06 Capital IQ Consensus Estimate; sees Q4 revs of $5.3-5.4 bln vs. $5.68 bln Capital IQ Consensus Estimate. 

=Teva Pharma (TEVA) reported earnings on Thur 3 Aug 2017 (b/o)

• Teva Pharmaceutical  has been without a permanent CEO for six months
• revealed the full extent of the challenges facing its next leader by announcing more job cuts, a retreat from 45 markets and a steep cut to its dividend 

JERUSALEM, Aug 3 (Reuters) - Israeli drugs group Teva Pharmaceutical Industrial Industries reported a steeper than expected 18.4 percent drop in second-quarter earnings on Thursday, due to weaker prices in the United States, and cut its interim dividend by 75 percent.

Teva, the world's largest generics drugmaker, said it earned $1.02 per share excluding one-off items in the second quarter, down from $1.25 a share in the same period last year. Revenue rose 13 percent to $5.7 billion.

It cut the quarterly dividend payout to $0.085 per ordinary share from $0.34.

Teva, which bought Allergan's generics business for $40.5 billion in August, was expected by analysts to have earned $1.06 per share on revenue of $5.72 billion, according to Thomson Reuters I/B/E/S Estimates.

Teva was left without a permanent chief executive in February after Erez Vigodman stepped down, leaving new management to restore confidence in the world's biggest generic drugmaker after a series of missteps. Its chief financial officer has also said he will step down in the next few months.

Global sales of Teva's best-selling multiple sclerosis drug Copaxone fell 10 percent in the quarter to $1.02 billion.

As a result the company has cut its full-year earnings forecast to $4.30-$4.50 a share from $4.90-$5.30 previously on revenues now expected to total $22.8-$23.2 billion, down from its previous forecast of $23.8 billion-$24.5 billion.

"This adjusted outlook takes into consideration the impact of increased price erosion in our U.S. generics business, which is expected to be in a high single-digits rate through the remainder of the year, and delays in generic launches in the U.S.," Teva said.

It added that the outlook for the business also reflected the continued deterioration in political and economic conditions in Venezuela, but it assumed no generic competition to its Copaxone 40mg version in the United States in 2017.

Earlier Teva said it would continue to pursue a breach of contract suit against the former owners of its Rimsa plant in Mexico after a New York judge rejected Teva's claim of fraud. 

=Teva Pharma (TEVA) reported earnings on Mon 13 Feb 2017 (b/o)

Teva Pharma beats by $0.02, beats on revs; reaffirms FY17 EPS and rev guidance :

• Reports Q4 (Dec) earnings of $1.38 per share, excluding non-recurring items, $0.02 better than the Capital IQ Consensus of $1.36; revenues rose 33.0% year/year to $6.49 bln vs the $6.26 bln Capital IQ Consensus, primarily due to the inclusion, following the closing on August 2, of the results of the Actavis Generics business.
  • Generic medicines revenues in the fourth quarter of 2016 were $3.7 billion, an increase of 44% compared to the fourth quarter of 2015, reflecting the results of the Actavis Generics business from August 2, 2016; generic medicines segment generated profit of $1.1 billion in the fourth quarter of 2016, an increase of 55% compared to the fourth quarter of 2015. Generic medicines profitability as a percentage of generic medicines revenues was 28.9% in the fourth quarter of 2016, up from 26.9% in the fourth quarter of 2015.
  • Specialty medicines revenues in the fourth quarter of 2016 were $2.2 billion, up 4% compared to the fourth quarter of 2015; segment profit was $1.1 billion in the fourth quarter of 2016, up 9% compared to the fourth quarter of 2015. U.S. specialty medicines revenues were $1.7 billion, up 5% compared to the fourth quarter of 2015.
  • Global revenues of Copaxone (20 mg/mL and 40 mg/mL), the leading multiple sclerosis therapy in the U.S. and globally, were $1.0 billion, an increase of 6% compared to the fourth quarter of 2015. Copaxone revenues in the United States were $829 million, up 9% compared to $760 million in the fourth quarter of 2015, mainly due to a price increase of 7.9% in January 2016. At the end of Q4, according to December 2016 IMS data, U.S. market shares for the Copaxone products in terms of new and total prescriptions were 27.9% and 29.3%, respectively. Copaxone 40 mg/mL accounted for over 84% of total Copaxone prescriptions in the U.S. Copaxone revenues outside the United States were $186 million, a decrease of 7%, compared to the fourth quarter of 2015 mainly due to loss of tender orders in Russia, partially offset by a volume increase in Europe.
• Co reaffirms guidance for FY17, sees EPS of $4.90-5.30, excluding non-recurring items, vs. $4.89 Capital IQ Consensus Estimate; sees FY17 revs of $23.8-24.5 bln vs. $23.77 bln Capital IQ Consensus Estimate.
• Interim, CEO: "With the entire Teva team, I am conducting a thorough review of the business to find additional opportunities to enhance value."

=Teva Pharma (TEVA) reported earnings on Tue 15 November 2016 (b/o)

Teva Pharma beats by $0.03, misses on revs; guides Q4 EPS in-line, revs in-line; guides FY16 EPS in-line, revs in-line :

• Reports Q3 (Sep) earnings of $1.31 per share, $0.03 better than the Capital IQ Consensus of $1.28; revenues rose 15.3% year/year to $5.56 bln vs the $5.71 bln Capital IQ Consensus.
  • Non-GAAP gross profit margin was 61.0% in the third quarter of 2016, compared to 61.8% in the third quarter of 2015.
  • Generic medicines revenues in the third quarter of 2016 were $2.9 bln, an increase of 32% compared to the third quarter of 2015, reflecting the results of operations of the Actavis generics business from August 2, 2016. In local currency terms, revenues increased 35%.
  • Specialty medicines revenues in the third quarter of 2016 were $2.0 bln, a decrease of 6% compared to the third quarter of 2015. U.S. specialty medicines revenues were $1.6 bln, down 8% compared to the third quarter of 2015.
• Co issues in-line guidance for Q4, sees EPS of $1.34-1.44 vs. $1.43 Capital IQ Consensus Estimate; sees Q4 revs of $6.2-6.5 bln vs. $6.48 bln Capital IQ Consensus Estimate.
• Co issues in-line guidance for FY16, sees EPS of $5.10-5.20 vs. $5.18 Capital IQ Consensus Estimate; sees FY16 revs of $21.6-21.9 vs. $22.1 bln Capital IQ Consensus Estimate.
• "We were also pleased to report this quarter that we have successfully completed the second pivotal phase three study for SD-809 for tardive dyskinesia and plan to submit that NDA to the U.S. FDA at the end of this year, and have also resubmitted SD-809 for Huntington disease in response to the FDA's Complete Response Letter. Going forward, we will focus on also growing our specialty pipeline through in-house opportunities, including in the development and commercialization of our key pipeline assets, most notably our anti-CGRP product for migraine headaches and fasinumab. In the face of the industry and company-specific challenges we have been dealing with this year, we remain excited about the future as we strive to create a platform that is unique to the industry, working every day to find the delicate balance between access and innovation and laying the foundation for Teva's continued growth."